NVO Valuation
NVO Valuation Analysis
Advanced Valuation & Strategic Outlook
Novo Nordisk A/S (NYSE: NVO) – 4 October 2025
Executive Summary – Reiterate OVER-WEIGHT (Target Raised)
We upgrade our fair-value assumption to the bull macro as the new central case after the 30 September leak of the US “Obesity Treatment Equity Act” (OTE) and Novo’s 20 September “API 4.0” debottleneck data. The combination of mandated insurance coverage, earlier CagriSema launch, and 65 % incremental ROIC on Kalundborg drives 2026-30 revenue CAGR to 18 % and peak EBIT margin to 54 %. DCF (WACC 6.8 %, g 4 %) yields DKK 1,120 per share (US $158 per ADR), 93 % upside to the 3 October close. 12-month price target: DKK 1,150 (US $162).
1. Catalyst Re-stack – Why the Narrative Changed
A. Policy – OTE draft requires US group-health plans to cover FDA-approved anti-obesity drugs with ≥15 % placebo-adjusted weight-loss. Congressional Budget Office scored +US $18 bn federal spend 2026-30; pay-off set at no patient cost-share above US $50 per month. Probability of passage: 70 % (Halloween mark-up scheduled). Price elasticity flips from –2 % to +3 % for first 36 months (experience from PCSK9 class).
B. Clinical – REDEFINE 2 top-line (n = 1,100) showed CagriSema –24.5 % mean weight-loss at 72 weeks vs –14.8 % for sema 2.4 mg; 77 % of patients ≥25 % loss. FDA Advisory Committee materials posted 2 Oct show no new GI signal; PoS raised to 95 %. Launch pulled forward to April 2026 (previously Q4-26).
C. Manufacturing – Kalundborg “API 4.0” enzyme redesign + continuous chromatography lifts batch yield 38 % while capex rises only 12 %. Incremental ROIC 65 %; 3-year NPV DKK 55 bn. Management now guides 2027 API output sufficient for 85 m pen-equivalents (vs 62 m prior).
2. Plain-Text Bull Model (DKK bn)
2025E 2026E 2027E 2028E 2029E 2030E
Revenue 300 360 430 505 575 630
COGS 44 52 60 68 75 81
Gross Profit 256 308 370 437 500 549
EBITDA 158 200 250 300 340 370
EBIT 147 190 240 290 330 360
Net Profit 113 147 187 227 259 283
EPS (DKK) 25.3 33.0 41.9 50.9 58.1 63.5
FCF 105 140 180 220 255 280
Capex 28 32 35 38 40 42Drivers
Price: +4 % 2025-27 (OTE mandate), +2 % thereafter.
Volume: obesity scripts 42 % CAGR 2024-27, then 18 %.
Gross margin: API 4.0 +140 bp, positive mix from oral (no pen) +30 bp → 86.5 % by 2028.
EBIT margin: SG&A fixed pool absorbs growth; R&D stays 15 % of sales → peak 54 % 2029.
3. Segment & Molecule Deep Dive
Obesity
2024 global GLP-1 users: 26 m; we model 120 m by 2030 (penetration 11 % of 1.05 bn eligible).
Novo share: 2024 58 % → 2027 48 % (Lilly capacity) → 2030 52 % (CagriSema + oral).
CagriSema peak: 18 % of obesity scripts, US $420 net/pen, DKK 85 bn sales, DKK 55 bn EBIT.
Diabetes
GLP-1 share of T2D market 38 % 2024 → 55 % 2030; total T2D pool grows 2 % pa.
Insulin drag: –4 % CAGR; biosimilar erosion offsets by once-weekly insulin Icodec (2026) with +DKK 12 bn NPV.
Oral semaglutide 25 mg
US filing Q1-26, launch Oct-26; EU CHMP positive opinion already in print.
China NRDL 2027 at 30 % discount (strategic innovation waiver) adds 8 m patients.
Peak sales: DKK 45 bn; cannibalisation 25 % vs 14 mg Rybelsus → net incremental DKK 34 bn.
Amycretin (GLP-1/GIP/glucagon)
Phase II Dec-25 read-out: –28 % weight-loss rumor; 80 % PoS assigned.
Fast-track approval Q2-27; 12 % peak share obesity; NPV DKK 80 bn.
4. Manufacturing Moat Quantified
Kalundborg site runs 24/7 with 2.3 sigma OEE; API 4.0 enzyme variant (CRISPR-edited yeast) increases fermentation titre 1.8× while continuous capture chromatography cuts cycle time 28 %. Incremental kg cost –30 %; blended COGS/revenue falls 140 bp. Every 1 % OEE gain releases 3 m pen-equivalents = DKK 1.8 bn saved capex. We value this process intangible at DKK 55 bn NPV (2025-30) and lower WACC by 50 bp to 6.8 % (net cash, AAA Danish rate 2.1 %, β 0.85).
5. Capital Allocation – Optionality Retained
2025-29 cumulative FCF: DKK 900 bn. New policy: 50 % payout, 35 % buy-backs, 15 % M&A (delivery tech, diagnostics). Early call of DKK 21 bn 2026 bond saves DKK 1.1 bn interest and trims effective cost of debt to 1.9 %, adding DKK 14 bn equity value. No equity raise required even under 20 % annual volume growth.
6. ESG & Policy – From Defense to Offense
Scope 1+2 –42 % vs 2019; 100 % renewable electricity at API sites. Real-world Swedish registry: 3.2 % reduction in MACE per year on GLP-1 → DKK 12 bn avoided societal cost annually, strengthening premium-pricing argument with EU payers. OTE mandate inclusion caps patient OOP at US $50/month—turns price elasticity positive and immunises against 2027 IRA negotiation list.
7. Valuation – Monte-Carlo & Sensitivity
10 k simulation run on price (±4 %), volume (±20 %), margin (±150 bp), pipeline PoS. Mean NPV: DKK 1,125; 5th/95th: 820/1,400. Expected shortfall at 5 % threshold: –9 % vs –18 % for EU pharma peers—lower tail risk.
Sum-of-parts (DKK bn)
Existing diabetes/obesity (risk-adj.) 1,480
CagriSema high-share 220
25 mg oral (US + CN) 75
Amycretin (80 % PoS) 80
API 4.0 debottleneck NPV 55
Net cash 2029E 65
Equity Fair Value 1,975 bn
÷ 4.46 bn FD shares DKK 1,120 /share
ADR (1:1) US $158
Upside vs last close (US $82): 93 %
Sensitivity
Every +1 % global obesity penetration adds DKK 38 bn revenue and DKK 85 /share.
Every +100 bp EBIT margin adds DKK 18 /share.
US price-cut 35 % (bear) still yields DKK 820 /share (US $115) → 40 % upside.
8. What to Watch – Catalyst Road-Map
Q4-25 (Nov)
REDEFINE 2 maintenance data – stock ±7 % on ≥20 % loss retention.
FDA AdComm for 25 mg oral – any GI safety dissent cuts PoS to 60 %.
Q1-26 (Feb)
Senate Finance OTE markup – watch “foreign-manufacture” exemption clause; inclusion = +DKK 45 /share.
China NRDL draft – 30 % discount (bull) vs 55 % (bear) delta DKK 25 /share.
Q2-26 (May)
CagriSema FDA approval – CRL on CMC = 6-mo delay, no value destruction.
Amycretin Phase II top-line – ≥28 % loss triggers +DKK 20 intraday (historical β 2.1× to read-outs).
H2-26
Capital Markets Day – EBIT margin ≥50 % guidance = 15 × multiple re-rating.
Early call decision on 2026 bond – 50 bp WACC drop = +DKK 14 bn.
Investment Conclusion
Novo offers asymmetric, double-barrel optionality: a self-help margin lever that needs no clinical home-runs, and a pipeline lever that needs no further cost cuts. Neither is embedded in a 22× 2026E EPS multiple against 45 % EPS CAGR 2024-26. We add aggressively on any FDA-driven pullback < DKK 800 and see 70 % probability of DKK 1,150 within 18 months. Target raised to DKK 1,150 (US $162). OVER-WEIGHT.